Literature DB >> 23232549

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

M S Hershfield1, J T Callaghan, W Tassaneeyakul, T Mushiroda, C F Thorn, T E Klein, M T M Lee.   

Abstract

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23232549      PMCID: PMC3564416          DOI: 10.1038/clpt.2012.209

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

1.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

2.  British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

Authors:  Kelsey M Jordan; J Stewart Cameron; Michael Snaith; Weiya Zhang; Michael Doherty; Jonathan Seckl; Aroon Hingorani; Richard Jaques; George Nuki
Journal:  Rheumatology (Oxford)       Date:  2007-05-23       Impact factor: 7.580

3.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

4.  Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Authors:  Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

Review 5.  Population biology of antigen presentation by MHC class I molecules.

Authors:  P Parham; T Ohta
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

6.  A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Authors:  M Tohkin; N Kaniwa; Y Saito; E Sugiyama; K Kurose; J Nishikawa; R Hasegawa; M Aihara; K Matsunaga; M Abe; H Furuya; Y Takahashi; H Ikeda; M Muramatsu; M Ueta; C Sotozono; S Kinoshita; Z Ikezawa
Journal:  Pharmacogenomics J       Date:  2011-09-13       Impact factor: 3.550

7.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

Review 8.  Pharmacological interaction of drugs with immune receptors: the p-i concept.

Authors:  Werner J Pichler; Andreas Beeler; Monika Keller; Marianne Lerch; Sinforiano Posadas; Daphné Schmid; Zoi Spanou; Anna Zawodniak; Basil Gerber
Journal:  Allergol Int       Date:  2006-03       Impact factor: 5.836

Review 9.  Human leukocyte antigens and drug hypersensitivity.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Yuan-Tsong Chen
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-08

Review 10.  Gene map of the extended human MHC.

Authors:  Roger Horton; Laurens Wilming; Vikki Rand; Ruth C Lovering; Elspeth A Bruford; Varsha K Khodiyar; Michael J Lush; Sue Povey; C Conover Talbot; Mathew W Wright; Hester M Wain; John Trowsdale; Andreas Ziegler; Stephan Beck
Journal:  Nat Rev Genet       Date:  2004-12       Impact factor: 53.242

View more
  66 in total

1.  Study of epidemiological aspects of hyperuricemia in Poland.

Authors:  Katarzyna Kostka-Jeziorny; Krystyna Widecka; Andrzej Tykarski
Journal:  Cardiol J       Date:  2019-06-21       Impact factor: 2.737

2.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

Review 3.  Essential Characteristics of Pharmacogenomics Study Publications.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

Review 4.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

5.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

6.  Pharmacogenetics in clinical practice: how far have we come and where are we going?

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

7.  Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population.

Authors:  X Liu; J Sun; H Yu; H Chen; J Wang; H Zou; D Lu; J Xu; S L Zheng
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

Review 8.  Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Authors:  Roxana Daneshjou; Rachel Huddart; Teri E Klein; Russ B Altman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

9.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

10.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.